Glycoengineered obinutuzumab induces higher levels of TNF-α, IL-6, and IL-8 than wild-type rituximab. CLL whole blood was incubated for 2, 6, or 24 hours in the presence of 10 µg/mL of nonglycoengineered wild-type rituximab (WT-RTX, open squares), glycoengineered obinutuzumab (GE-OBZ, closed squares), control antibody cetuximab (CTRL, open circles), or 0.1 µM of PMA (closed circles). TNF-α (A), IL-6 (B), and IL-8 (C) in plasma were measured by flow cytometry using calibrated beads. The results are the means and standard deviations of 3 independent experiments.